3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Carcinoma
3
Mesothelioma
2
Uterine Cervical Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
1
Non Small Cell Lung Cancer NSCLC
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
Interventions
trastuzumab deruxtecan
4
eribulin
3
Capecitabine
3
Trastuzumab
2
Paclitaxel
2
Gemcitabine
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
telisotuzumab vedotin
1
taxane
1
pertuzumab
1
pembrolizumab
1
osimertinib
1
olaparib
1
margetuximab
1
exemestane
1
entrectinib
1
encorafenib
1
dacomitinib
1
capmatinib
1
binimetinib
1
adagrasib
1
abemaciclib
1
Vinorelbine
1
Vemurafenib
1
Pemetrexed
1
Imlunestrant
1
Gefitinib
1
Fulvestrant
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Neoplasm Metastasis
×
Pemetrexed
×
Clear all
NCT04035486
2025-10-10
FLAURA2
AstraZeneca
Phase 3
Active not recruiting
587 enrolled
44 charts
1 FDA